This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butler, G. S.
Right arrow Articles by Overall, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butler, G. S.
Right arrow Articles by Overall, C. M.

 Previous Article

Molecular and Cellular Biology, August 2008, p. 4896-4914, Vol. 28, No. 15
0270-7306/08/$08.00+0     doi:10.1128/MCB.01775-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding {triangledown} ,{ddagger}

Georgina S. Butler,1 Richard A. Dean,1 Eric M. Tam,2,{dagger} and Christopher M. Overall1,2*

Departments of Oral Biological and Medical Sciences,1 Biochemistry and Molecular Biology, Centre for Blood Research, Life Sciences Centre, University of British Columbia, Vancouver, Canada2

Received 27 September 2007/ Returned for modification 3 November 2007/ Accepted 18 May 2008

Broad-spectrum matrix metalloproteinase (MMP) inhibitors (MMPI) were unsuccessful in cancer clinical trials, partly due to side effects resulting from limited knowledge of the full repertoire of MMP substrates, termed the substrate degradome, and hence the in vivo functions of MMPs. To gain further insight into the degradome of MMP-14 (membrane type 1 MMP) an MMPI, prinomastat (drug code AG3340), was used to reduce proteolytic processing and ectodomain shedding in human MDA-MB-231 breast cancer cells transfected with MMP-14. We report a quantitative proteomic evaluation of the targets and effects of the inhibitor in this cell-based system. Proteins in cell-conditioned medium (the secretome) and membrane fractions with levels that were modulated by the MMPI were identified by isotope-coded affinity tag (ICAT) labeling and tandem mass spectrometry. Comparisons of the expression of MMP-14 with that of a vector control resulted in increased MMP-14/vector ICAT ratios for many proteins in conditioned medium, indicating MMP-14-mediated ectodomain shedding. Following MMPI treatment, the MMPI/vehicle ICAT ratio was reversed, suggesting that MMP-14-mediated shedding of these proteins was blocked by the inhibitor. The reduction in shedding or the release of substrates from pericellular sites in the presence of the MMPI was frequently accompanied by the accumulation of the protein in the plasma membrane, as indicated by high MMPI/vehicle ICAT ratios. Considered together, this is a strong predictor of biologically relevant substrates cleaved in the cellular context that led to the identification of many undescribed MMP-14 substrates, 20 of which we validated biochemically, including DJ-1, galectin-1, Hsp90{alpha}, pentraxin 3, progranulin, Cyr61, peptidyl-prolyl cis-trans isomerase A, and dickkopf-1. Other proteins with altered levels, such as Kunitz-type protease inhibitor 1 and beta-2-microglobulin, were not substrates in biochemical assays, suggesting an indirect affect of the MMPI, which might be important in drug development as biomarkers or, in preclinical phases, to predict systemic drug actions and adverse side effects. Hence, this approach describes the dynamic pattern of cell membrane ectodomain shedding and its perturbation upon metalloproteinase drug treatment.

* Corresponding author. Mailing address: Centre for Blood Research, Life Sciences Institute, Room 4.401, 2350 Health Sciences Mall, University of British Columbia, Vancouver, B.C. V6T 1Z3, Canada. Phone: (604) 822-2958. Fax: (604) 822-7742. E-mail: chris.overall{at}ubc.ca

{triangledown} Published ahead of print on 27 May 2008.

{ddagger} Supplemental material for this article may be found at http://mcb.asm.org/.

{dagger} Present address: Dept. of Protein Engineering, Genetech Inc., South San Francisco, CA 94080.

Molecular and Cellular Biology, August 2008, p. 4896-4914, Vol. 28, No. 15
0270-7306/08/$08.00+0     doi:10.1128/MCB.01775-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Doucet, A., Butler, G. S., Rodriguez, D., Prudova, A., Overall, C. M. (2008). Metadegradomics: Toward in Vivo Quantitative Degradomics of Proteolytic Post-translational Modifications of the Cancer Proteome. Mol. Cell. Proteomics 7: 1925-1951 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»